Evidence map›Paper›PMID 32023469›Full record

ArticleCell reports2020

Neonatal Rhesus Macaques Have Distinct Immune Cell Transcriptional Profiles following HIV Envelope Immunization.

Qifeng Han, Todd Bradley, Wilton B Williams, Derek W Cain, David C Montefiori, Kevin O Saunders, Robert J Parks, Regina W Edwards, Guido Ferrari, Olaf Mueller and 15 more

Open access · goldAbstract read
In one paragraph

Article in Cell reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Microbiome Studies in Non-human Primates.Current HIV/AIDS reports · 2021
    Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 6 institutions in 1 country.

Qifeng HanDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Todd BradleyDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Wilton B WilliamsDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Derek W CainDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
David C MontefioriDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Kevin O SaundersDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Robert J ParksDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Regina W EdwardsDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Guido FerrariDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Olaf MuellerCenter for Genomics of Microbial Systems, Duke University Medical Center, Durham, NC, USA.
Xiaoying ShenDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Kevin J WieheDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Steven ReedIDRI, Seattle, WA, USA.
Christopher B FoxIDRI, Seattle, WA, USA.
Wes RountreeDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Nathan A VandergriftDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Yunfei WangDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Laura L SutherlandDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Sampa SantraCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
M Anthony MoodyDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Sallie R PermarDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Georgia D TomarasDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Mark G LewisBIOQUAL, Inc., Rockville, MD, USA.
Koen K A Van RompayCalifornia National Primate Research Center, University of California, Davis, Davis, CA, USA.
Barton F HaynesDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA. Electronic address: barton.haynes@dm.duke.edu.
Duke University · USInfectious Disease Research Institute · USBeth Israel Deaconess Medical Center · USBioqual · USDuke Medical Center · USUniversity of California, Davis · US

Funding

Virus biology scientific research support componentUM1AI100645 · NIAID · DUKE UNIVERSITY · PI MONTEFIORI, DAVID C · 2012 to 2018
$204.7M
National Institute on Aging (NIA) ColonyP51OD011107 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Simon J. Atkinson · 2012 to 2026
$191.5M
Nonhuman primate studies for development of a prototype HIV vaccine that induces broadly neutralizing antibodiesUM1AI144371 · NIAID · DUKE UNIVERSITY · PI HAYNES, BARTON F. · 2019 to 2025
$190.4M
Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI GEORGIA Doris TOMARAS · 2005 to 2026
$50.5M
Virus and Antibody Gene Sequencing CoreP01AI131251 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Kevin Wiehe · 2017 to 2026
$40.7M
Translational Science InitiativeP40OD012217 · OD · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI CARLOS A SARIOL · 2012 to 2026
$40.4M
HIV-1 vaccine-elicited antibodies target envelope glycansR01AI120801 · NIAID · DUKE UNIVERSITY · PI SAUNDERS, KEVIN O · 2015 to 2024
$7.5M
Neonatal Immunity to novel TF SHIVsR01AI140897 · NIAID · DUKE UNIVERSITY · PI WILLIAMS, WILTON B · 2018 to 2022
$4.4M
Neonatal Immunity to novel TF SHIVsR37AI140897 · NIAID · DUKE UNIVERSITY · PI Wilton B Williams · 2024 to 2026
$2.4M
NIAID NIH HHS P01 AI131251NIAID NIH HHS P30 AI064518NIAID NIH HHS R01 AI120801NIAID NIH HHS R01 AI140897NIAID NIH HHS R37 AI140897NIAID NIH HHS UM1 AI100645NIAID NIH HHS UM1 AI144371NIH HHS P40 OD012217NIH HHS P51 OD011107
6 · The paper itself

Abstract

HIV-1-infected infants develop broadly neutralizing antibodies (bnAbs) more rapidly than adults, suggesting differences in the neonatal versus adult responses to the HIV-1 envelope (Env). Here, trimeric forms of HIV-1 Env immunogens elicit increased gp120- and gp41-specific antibodies more rapidly in neonatal macaques than adult macaques. Transcriptome analyses of neonatal versus adult immune cells after Env vaccination reveal that neonatal macaques have higher levels of the apoptosis regulator BCL2 in T cells and lower levels of the immunosuppressive interleukin-10 (IL-10) receptor alpha (IL10RA) mRNA transcripts in T cells, B cells, natural killer (NK) cells, and monocytes. In addition, immunized neonatal macaques exhibit increased frequencies of activated blood T follicular helper-like (Tfh) cells compared to adults. Thus, neonatal macaques have transcriptome signatures of decreased immunosuppression and apoptosis compared with adult macaques, providing an immune landscape conducive to early-life immunization prior to sexual debut.

Indexed as

ImmunizationTranscription, GeneticAIDS VaccinesAnimalsAnimals, NewbornAntibodies, NeutralizingAntibody FormationFecesHIV-1HIV InfectionsLymphocyte ActivationLymphocyte SubsetsMacaca mulattaMicrobiotaMonocytesRNA, MessengerAIDS VaccinesAntibodies, NeutralizingRNA, MessengerViral Envelope ProteinsHIV-1 envelopeimmunizationneonatesrhesus macaquessingle-cell RNA sequencingtranscriptome

Identifiers

PMID32023469
PMCPMC7243677
OpenAlexW3004780794

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.